

Broadloom Herbicide

Evaluation Report for Category B Streamlined, Subcategory 3.10 Application

Application Number: 2023-2773
Application: Category B, Subcategory 3.10 Application (new or changes to product labels – tank mixes)
Product: Broadloom Herbicide
Registration Number: Reg. No. 32661
Active ingredient (a.i.): bentazon (present as sodium salt) [BZN]
PMRA Document Number : 3502883

Purpose of Application

The purpose of this application was to amend the registration of Broadloom Herbicide per the following:

1. replace a specific list of currently labelled imazethapyr tank mix partners with general ‘imazethapyr’ for permitted products that may be tank mixed with Broadloom Herbicide; and
2. add two supplement products, Ohm and Wave, as tank mix partners for post-emergent use with Broadloom Herbicide on all labelled crops.

Chemistry, Health and Environmental Assessments

A chemistry assessment was not required since there was no change to product chemistry. Health and Environmental assessments were not required since the use pattern, including host crops, application rates and timings of the product, remained unchanged.

Value Assessment

Labelling the general active ingredient name imazethapyr as tank mix partner for use with Broadloom Herbicide, as well as the two supplement products, Ohm and Wave, allows growers to select their preferred and/or available imazethapyr herbicide to use with Broadloom Herbicide, as well as provide greater flexibility when tank mixing with a supplement product is desired.

Precedent product registrations, in conjunction with similar registration amendments previously reviewed for other herbicide end-use products (EPs), demonstrated that acceptable value (efficacy and crop tolerance) would be expected when Broadloom Herbicide is applied in tank mixture with imazethapyr EPs, as well as with Ohm and Wave supplement EPs.

Conclusion

The PMRA has completed an evaluation of the subject application and has found the information sufficient to amend the registration of Broadloom Herbicide to include the requested label amendments.

References

None.

© His Majesty the King in Right of Canada, as represented by the Minister of Health Canada, 2023

All rights reserved. No part of this information (publication or product) may be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, or stored in a retrieval system, without prior written permission of Health Canada, Ottawa, Ontario K1A 0K9.